Skip to main content
. 2016 Jun 8;6:27455. doi: 10.1038/srep27455

Figure 3. Baculovirus as a gene transfer vector for bladder cancer therapy.

Figure 3

(A) Bladder weight measurement. Left: The animal experiment protocol used. Mice were inoculated with MB49 tumor cells intravesically and subsequently treated three times with baculoviral vectors (days 7, 14, and 21). Right: Mice were treated with baculoviral vectors expressing CD40L, IL-15, or both. Control animals were treated with PBS, BCG, or empty baculoviral vector BacPAK6. Mice were sacrificed on day 35 post-tumor inoculation and bladders were collected for weight measurement. The data represent mean + s.d., n = 5 per group. (B) Survival curves to demonstrate anti-tumor effects of baculoviral gene therapy after 3 instillations in the mouse bladder. The tumor inoculation and virus/BCG instillations were performed as shown in (A). Survival curves till day 125 are shown. The statistical analysis was performed using the log rank test. n = 20 for PBS, BacPAK6, and BCG groups and 10 for BV-CD40L, BV-IL-15 and BV-CD40L+BV-IL-15 groups. (C) H&E staining shows MB49 bladder tumor development. Bladders were collected on day 35 post-tumor inoculation.